Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NCT03186898
Recruiting
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Emory Proton Therapy Center, Atlanta, Georgia +25 locations
Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Register for Updates
Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)
NCT04895306
Recruiting
The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, physical function and quality of life when compared with placebo in women with chronic back pain treated with opioids who have low testosterone.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
05/06/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pain, Opioid Use, Androgen Deficiency, Back Pain
Register for Updates
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367
Recruiting
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +261 locations
Conditions: Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Exocrine Pancreas Carcinoma
Register for Updates
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213
Recruiting
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation preve... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +290 locations
Conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Prostate Adenocarcinoma
Register for Updates
Exercise Prehabilitation for Locoregional Esophageal Cancer
NCT06430346
Recruiting
The purpose of the study is to examine the feasibility and acceptability of exercise "prehabilitation" for patients preparing for esophageal cancer resection (removal).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Esophageal Cancer
Register for Updates
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
NCT06654037
Recruiting
This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to treatment (refractory). Abemaciclib, a type of cyclin-dependent kinase inhibitor, blocks certain proteins, which may help keep tumor cells from growing. 5-fluorouracil, a type of antimetabo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +3 locations
Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Register for Updates
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
NCT06935266
Recruiting
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous \[SC\] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels. Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment \[EOT\]).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/06/2025
Locations: Celerion, Tempe, Arizona
Conditions: Healthy Volunteers
Register for Updates
NIAID Centralized Sequencing Protocol
NCT03206099
Recruiting
Background: Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems. Objective: To understand the genetics of immune disorders various health conditions, as well as outcomes of cli... Read More
Gender:
ALL
Ages:
Between 1 day and 100 years
Trial Updated:
05/06/2025
Locations: Children's National Health System, Washington, District of Columbia +1 locations
Conditions: Atopy, Primary Immunodeficiency, Autoimmunity, Autoinflammation
Register for Updates
The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment
NCT04931095
Recruiting
This study will evaluate the individual and interactive effects of oral cannabis and alcohol on subjective and behavioral measures of impairment.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
05/06/2025
Locations: Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Cannabis Intoxication, Alcohol Intoxication
Register for Updates
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393
Recruiting
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division a... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
05/06/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +133 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Semaglutide Therapy for Alcohol Reduction (STAR)
NCT06015893
Recruiting
Background: Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed. Objective: To test if a medication named Semaglutide is safe and may reduce alcohol drinking in people with AUD. Who can participate? All Adults aged 18 or older with AUD might be eligible to participate in the study. What will... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
05/06/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Addiction, Alcohol Use Disorder
Register for Updates
Bionic Pancreas in CFRD
NCT06449677
Recruiting
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to us... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
05/06/2025
Locations: University of Colorado-Barbara Davis Center for Diabetes, Aurora, Colorado +12 locations
Conditions: Cystic Fibrosis-related Diabetes
Register for Updates